NSE · APRAMEYA · Healthcare
Aprameya Engineering Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹56 Cr with net profit ₹5 Cr — a 9.17% net margin, versus 11.82% the period before.
Shareholding
As of 2026-03-31
- Promoter74.05%
- Public25.24%
- DII0.7%
933 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 3.53× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Healthcare · ranked #1 of 85 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Apollo Hospitals Enter. Limited | ₹1,26,078 Cr | 59.92 | 13.3 | 20.48% | 7.91% |
| Max Healthcare Institute Ltd. | ₹1,00,932 Cr | 67.43 | 9.39 | 13.42% | 16.73% |
| Manipal Health Enterpri Limited | ₹94,911 Cr | 101.2 | 5.78 | 10.59% | 7.81% |
| Fortis Healthcare Ltd. | ₹66,897 Cr | 62.71 | 6.76 | 10.53% | 11.02% |
| Aster DM Quality Care Ltd. | ₹66,465 Cr | 171.35 | 15.8 | 8.48% | 6.54% |
| Global Health Limited | ₹38,287 Cr | 66.89 | 9.66 | 14.05% | 11.88% |
| Narayana Hrudayalaya Ltd. | ₹38,187 Cr | 44.3 | 8.41 | 17.76% | 9% |
| Krishna Institute of Medical Sciences Ltd. | ₹33,258 Cr | 159.33 | 8.87 | 10.74% | 4.85% |
| Dr. Lal Path Labs Ltd. | ₹32,306 Cr | 57.44 | 12.88 | 20.13% | 18.75% |
| Poly Medicure Ltd. | ₹17,288 Cr | 54.02 | 5.57 | 10.37% | 15.77% |
| Aprameya Engineering Ltd.(this company) | — | 42.81 | 3.12 | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashAprameya Engineering Ltd. reported revenue of Rs 136.3 Cr. The company had an EPS of 2.65 and a book value of 36.42. Its debt-to-equity ratio was 0.83, and ROCE stood at 31.01%. The PE ratio was 58.04.
Positives
- +Promoter holding increased from 73.5294% in Sep 2025 to 74.0546% in Mar 2026.
- +The company's ROCE was 31.01%, indicating efficient use of capital.
- +Promoters have not pledged any shares.
- +The latest annual revenue grew to Rs 136.2966 Cr in Mar 2025 from Rs 65.6222 Cr in Mar 2024.
Negatives
- −The debt-to-equity ratio of 0.83 indicates a notable level of debt.
- −EPS has declined from 10.65 in Mar 2022 to 2.47 in Mar 2024, before rising to 9.27 in Mar 2025.
- −FII holding decreased from 2.4685% in Sep 2024 to 0% in Mar 2026.
- −No dividend yield is available for the company.
Financial performance
Aprameya Engineering Ltd. recorded a revenue of Rs 136.3 Cr in March 2025. Annual revenue has shown variability, increasing from Rs 26.0123 Cr in Mar 2021 to Rs 136.2966 Cr in Mar 2025. Net profit also varied, reaching Rs 16.1161 Cr in Mar 2025 from Rs 0.86 Cr in Mar 2021. The latest annual EPS was 9.27 in Mar 2025.
Profitability & returns
The company's ROCE (Return on Capital Employed) was 31.01%. Annual EPS has fluctuated over the periods, from 0.61 in Mar 2021 to 9.27 in Mar 2025. The current EPS is 2.65. No data for profit margin or ROE was available. The company has not disclosed any dividend yield.
Balance sheet
Aprameya Engineering Ltd. has a debt-to-equity ratio of 0.83, indicating a significant reliance on debt financing. The book value per share was 36.42. No further information regarding assets or liabilities was provided. The company has not reported any pledged shares by promoters.
Ownership & pledges
Promoters held 74.0546% of the company's shares as of March 31, 2026. Public shareholding was 25.2416%, while Institutions held 0.7038%. There were no promoter shares pledged. The number of shareholders was 933. Promoter holding has increased from 73.5294% in September 2025 to 74.0546% in March 2026.
Data as of — price: 2026-09-17 · financials: Mar 26 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.